Table 4 Bisphosphonate use for individual drugs in cancer cases and controls, numbers and odds ratios (95% CIs) compared with non-use by database

From: Exposure to bisphosphonates and risk of common non-gastrointestinal cancers: series of nested case–control studies using two primary-care databases

  QResearch CPRD Combined analysis
  Cases/controls Adjusted * odds ratio (95% CI) P -value Cases/controls Adjusted * odds ratio (95% CI) P -value Pooled odds ratio (95% CI) P -value
Breast, alendronate Trend   0.7 Trend   0.04 Trend 0.3
Any use 901/4627 0.98 (0.89–1.07) 0.6 892/4648 0.96 (0.88–1.05) 0.3 0.97 (0.91–1.03) 0.3
Short term (less than a year) 409/2148 0.95 (0.85–1.08) 0.4 414/2085 1.00 (0.89–1.13) 0.9 0.98 (0.90–1.06) 0.6
Long term (at least a year) 492/2479 1.00 (0.89–1.12) 1.0 478/2563 0.92 (0.83–1.03) 0.2 0.96 (0.89–1.04) 0.3
Breast, etidronate Trend   0.1 Trend   0.8 Trend 0.2
Any use 453/2437 0.90 (0.81–1.01) 0.07 412/2246 0.91 (0.81–1.02) 0.1 0.91 (0.84–0.98) 0.02
Short term (less than a year) 176/893 0.95 (0.80–1.13) 0.6 179/1018 0.88 (0.74–1.03) 0.1 0.91 (0.81–1.03) 0.1
Long term (at least a year) 277/1544 0.87 (0.76–1.00) 0.05 233/1228 0.94 (0.81–1.09) 0.4 0.90 (0.82–1.00) 0.04
Breast, risedronate Trend   0.9 Trend   0.3 Trend 0.5
Any use 281/1537 0.92 (0.80–1.06) 0.2 279/1492 0.96 (0.84–1.11) 0.6 0.94 (0.85–1.04) 0.2
Short term (less than a year) 139/803 0.89 (0.73–1.07) 0.2 118/733 0.83 (0.68–1.02) 0.07 0.86 (0.75–0.99) 0.03
Long term (at least a year) 142/734 0.96 (0.80–1.16) 0.7 161/759 1.08 (0.90–1.29) 0.4 1.02 (0.90–1.17) 0.7
Prostate, alendronate Trend   0.009 Trend   0.05 Trend 0.001
Any use 292/1506 0.81 (0.70–0.93) 0.004 257/1299 0.88 (0.75–1.03) 0.1 0.84 (0.75–0.93) 0.001
Short term (less than a year) 142/692 0.86 (0.71–1.05) 0.1 120/591 0.91 (0.74–1.13) 0.4 0.89 (0.77–1.02) 0.1
Long term (at least a year) 150/814 0.75 (0.62–0.92) 0.004 137/708 0.86 (0.70–1.05) 0.1 0.80 (0.70–0.92) 0.002
Prostate, etidronate Trend   0.9 Trend   0.6 Trend 0.8
any use 141/567 1.06 (0.87–1.30) 0.5 104/496 0.88 (0.70–1.10) 0.3 0.98 (0.84–1.14) 0.8
Short term (less than a year) 55/223 1.10 (0.81–1.48) 0.6 34/209 0.69 (0.47–1.00) 0.05 0.91 (0.72–1.15) 0.4
Long term (at least a year) 86/344 1.04 (0.81–1.33) 0.8 70/287 1.02 (0.77–1.34) 0.9 1.03 (0.86–1.24) 0.8
Prostate, risedronate Trend   0.9 Trend   0.3 Trend 0.4
Any use 99/455 0.98 (0.77–1.23) 0.8 70/374 0.87 (0.66–1.13) 0.3 0.93 (0.78–1.10) 0.4
Short term (less than a year) 38/208 0.83 (0.58–1.18) 0.3 32/165 0.90 (0.61–1.33) 0.6 0.86 (0.66–1.12) 0.3
Long term (at least a year) 61/247 1.09 (0.81–1.46) 0.6 38/209 0.83 (0.58–1.19) 0.3 0.98 (0.78–1.23) 0.8
Lung, alendronate Trend   0.5 Trend   0.4 Trend 0.3
Any use 696/2542 1.00 (0.89–1.12) 0.9 756/2701 1.05 (0.94–1.18) 0.4 1.03 (0.95–1.11) 0.5
Short term (less than a year) 339/1114 1.07 (0.92–1.24) 0.4 386/1220 1.16 (1.01–1.34) 0.04 1.12 (1.01–1.24) 0.04
Long term (at least a year) 357/1428 0.93 (0.80–1.08) 0.3 370/1481 0.96 (0.83–1.11) 0.6 0.95 (0.85–1.05) 0.3
Lung, etidronate Trend   0.8 Trend   0.1 Trend 0.2
Any use 338/1262 1.04 (0.90–1.20) 0.6 356/1200 1.13 (0.98–1.31) 0.09 1.09 (0.98–1.20) 0.2
Short term (less than a year) 139/500 1.02 (0.82–1.27) 0.9 161/502 1.15 (0.94–1.42) 0.2 1.09 (0.94–1.27) 0.3
Long term (at least a year) 199/762 1.05 (0.87–1.26) 0.6 195/698 1.12 (0.93–1.35) 0.2 1.08 (0.95–1.24) 0.2
Lung, risedronate    0.9 Trend   0.7 Trend 0.7
Any use 261/848 1.02 (0.86–1.21) 0.8 252/829 1.11 (0.94–1.31) 0.2 1.06 (0.94–1.20) 0.3
Short term (less than a year) 125/380 1.05 (0.83–1.33) 0.7 126/412 1.06 (0.85–1.34) 0.6 1.06 (0.90–1.25) 0.5
Long term (at least a year) 136/468 0.98 (0.78–1.22) 0.8 126/417 1.13 (0.90–1.42) 0.3 1.05 (0.89–1.23) 0.6
  1. Abbreviations: CI=confidence interval; CPRD=Clinical Practice Research Datalink. *Adjusted for the confounders listed in the footnote for Table 2. Bold values indicate statistical significance.